Senzer's Pharmaceutical Inhaler Selected for Major Cannabinoid Patient Registry

London (ots/PRNewswire) - Senzer's pharmaceutical respiratory device will be
used in Europe's first and biggest national medical cannabis registry, Project
TWENTY21, in which an expected 20,000 patients will be enrolled by the end of
2021 creating the largest body of evidence for the efficacy of medical cannabis.

Drug Science, the leading independent scientific body on drugs in the UK running
Project TWENTY21, says the aim is to create "the largest body of evidence for
the effectiveness and tolerability of medical cannabis" so that policymakers may
be better informed about the possible benefits. Senzer is one of the launch
partners that will supply products for patients. Various preparations of
cannabinoids will be prescribed by affiliated doctors, and targeted conditions
include Anxiety Disorder, Chronic Pain, Epilepsy, Multiple Sclerosis, Post
Traumatic Stress Disorder, Substance Use Disorder, and Tourette's Syndrome.

Senzer's inhaler is CE-marked, approved as a Class II(a) Medical Device and will
soon be available in several EU countries. The inhaler is designed to ensure
cannabinoid formulations will quickly enter the bloodstream and the Company has
data to show that lower doses are needed to achieve clinical effectiveness.

"Senzer Pharmaceuticals is delighted to partner with Drug Science on Project
Twenty21," said Senzer CEO Alex Hearn. "Developing this critical body of
real-world data will support evidence-based decision-making for policymakers and
clinicians enabling wider access for UK patients to cannabis-based medicinal
products now, and in the future."

Drug Science said a key aim of the observational study was to ensure all 20,000
participants received pharmaceutical GMP-grade medical cannabis at an affordable
cost. It said Project TWENTY21 has the support from The Royal College of
Psychiatrists, The British Pain Society, the United Patients Alliance, as well
patients, peers and medical cannabis campaigners.

'Patients with severe debilitating conditions are being denied access to a life
changing medication,' said Drug Science CEO David Badcock. 'This happens because
prescribers lack the knowledge and confidence to prescribe medicinal cannabis or
the cannabis-based medicinal products are extortionately expensive. Project
Twenty21 will be using a two-pronged approach to address both of these issues
simultaneously and it is only possible with the ongoing support and assistance
of our launch partners.'

About SENZER

SENZER Ltd. is a U.K.-based inhalation technology company specializing in the
development and commercialization of therapeutic delivery systems of cannabinoid
products, and it is developing a pipeline of inhalation and delivery products to
meet unmet medical needs. Senzer's platform is based around a patented device
that allows swift and effective inhaled delivery of cannabinoids, in a
consistent dose-controlled presentation. The offering www.senzer.com

Logo - https://mma.prnewswire.com/media/1061849/Senzer_Logo.jpg

Contact:
Nicola Sturt
+44 (0)203-457-0453
press@senzer.com

Additional content: https://www.presseportal.de/pm/131299/4484775
OTS: Senzer Limited

Original-Content von: Senzer Limited, übermittelt durch news aktuell